Found: 26
Select item for more details and to access through your institution.
Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia.
- Published in:
- International Journal of Neuropsychopharmacology, 2015, v. 18, n. 6, p. 1, doi. 10.1093/ijnp/pyu098
- By:
- Publication type:
- Article
Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 10, p. 1655, doi. 10.3390/jpm12101655
- By:
- Publication type:
- Article
Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 9, p. N.PAG, doi. 10.3390/jpm12091449
- By:
- Publication type:
- Article
Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 3, p. 181, doi. 10.3390/jpm11030181
- By:
- Publication type:
- Article
Autoimmunity and immune system dysregulation in schizophrenia: IgGs from sera of patients hydrolyze myelin basic protein.
- Published in:
- Journal of Molecular Recognition, 2019, v. 32, n. 2, p. N.PAG, doi. 10.1002/jmr.2759
- By:
- Publication type:
- Article
Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome.
- Published in:
- Metabolites (2218-1989), 2023, v. 13, n. 3, p. 376, doi. 10.3390/metabo13030376
- By:
- Publication type:
- Article
Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome.
- Published in:
- Metabolites (2218-1989), 2022, v. 12, n. 9, p. 850, doi. 10.3390/metabo12090850
- By:
- Publication type:
- Article
Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study.
- Published in:
- Metabolites (2218-1989), 2021, v. 11, n. 1, p. 34, doi. 10.3390/metabo11010034
- By:
- Publication type:
- Article
Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia.
- Published in:
- Metabolites (2218-1989), 2020, v. 10, n. 10, p. 410, doi. 10.3390/metabo10100410
- By:
- Publication type:
- Article
Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia.
- Published in:
- Life (2075-1729), 2022, v. 12, n. 12, p. 1972, doi. 10.3390/life12121972
- By:
- Publication type:
- Article
Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals.
- Published in:
- Frontiers in Psychiatry, 2021, v. 12, p. 1, doi. 10.3389/fpsyt.2021.661174
- By:
- Publication type:
- Article
Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients.
- Published in:
- Pharmacogenomics & Personalized Medicine, 2021, v. 14, p. 1123, doi. 10.2147/PGPM.S327353
- By:
- Publication type:
- Article
Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 9, p. 1827, doi. 10.1111/bcp.14288
- By:
- Publication type:
- Article
A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.
- Published in:
- BMC Medical Genetics, 2019, v. 20, n. 1, p. N.PAG, doi. 10.1186/s12881-019-0773-3
- By:
- Publication type:
- Article
A distinct serum protein pattern in patients with paranoid schizophrenia.
- Published in:
- Physiology & Pharmacology, 2017, v. 21, n. 4, p. 304
- By:
- Publication type:
- Article
Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations.
- Published in:
- SAGE Open Medicine, 2016, v. 4, p. 1, doi. 10.1177/2050312116643673
- By:
- Publication type:
- Article
5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia.
- Published in:
- Frontiers in Molecular Neuroscience, 2020, v. 13, p. 1, doi. 10.3389/fnmol.2020.00063
- By:
- Publication type:
- Article
Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome.
- Published in:
- Diagnostics (2075-4418), 2020, v. 10, n. 9, p. 683, doi. 10.3390/diagnostics10090683
- By:
- Publication type:
- Article
Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia.
- Published in:
- Application of Clinical Genetics, 2020, v. 13, p. 97, doi. 10.2147/TACG.S247174
- By:
- Publication type:
- Article
The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia.
- Published in:
- Genes, 2023, v. 14, n. 3, p. 575, doi. 10.3390/genes14030575
- By:
- Publication type:
- Article
The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.
- Published in:
- Genes, 2022, v. 13, n. 8, p. 1312, doi. 10.3390/genes13081312
- By:
- Publication type:
- Article
Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome.
- Published in:
- Genes, 2022, v. 13, n. 5, p. 844, doi. 10.3390/genes13050844
- By:
- Publication type:
- Article
No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic‐induced tardive dyskinesia.
- Published in:
- Human Psychopharmacology: Clinical & Experimental, 2019, v. 34, n. 1, p. 1, doi. 10.1002/hup.2685
- By:
- Publication type:
- Article
Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia.
- Published in:
- Neuropsychiatric Disease & Treatment, 2020, v. 16, p. 1051, doi. 10.2147/NDT.S247161
- By:
- Publication type:
- Article
Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia.
- Published in:
- PLoS ONE, 2017, v. 12, n. 9, p. 1, doi. 10.1371/journal.pone.0183867
- By:
- Publication type:
- Article